Genscript Biotech Corporation
1548
Hisse Senetlerindeki Sıralama
#2099
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Hisse Fiyatı
$4.37
Piyasa Değeri
$9.84B
Değişim (1 gün)
2.30%
Değişim (1 yıl)
109.57%
Ülke
HK
Ticaret Genscript Biotech Corporation (1548)
Kategori
Healthcare
Genscript Biotech Corporation (1548) için gelir
Jun 2026 itibarıyla gelir TTM: $844.00M
Genscript Biotech Corporation şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $844.00M'dir. 2023 yılında şirketin geliri $839.53M önceki yıla göre artış 2022 yılındaki $625.70M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Genscript Biotech Corporation için 2013 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $844.00M | 41.97% |
| 2024 | $594.49M | -29.19% |
| 2023 | $839.53M | 34.17% |
| 2022 | $625.70M | 27.67% |
| 2021 | $490.10M | 25.39% |
| 2020 | $390.85M | 42.98% |
| 2019 | $273.35M | 18.33% |
| 2018 | $231.02M | 51.34% |
| 2017 | $152.65M | 33.04% |
| 2016 | $114.74M | 32.32% |
| 2015 | $86.71M | 23.88% |
| 2014 | $69.99M | 16.45% |
| 2013 | $60.10M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $12.62B | 1,395.77% |
US
|
|
| $2.23B | 163.98% |
US
|
|
| $15.74B | 1,765.44% |
AU
|
|
| $6.02B | 613.42% |
NL
|
|
| - | - |
CH
|
